Our data supports the hypothesis that the phenotype plasticity of MM (oncogenic/invasive state ZEB1high/TWIST1high) observed in BRAF mutated patients [23], responsible for disease progression and drug resistance [6,37], is recapitulated, at least in part, by NAMPT over-expression. The gene discussed is BRAF; the disease is Miyoshi myopathy.